Biotechnology Healthcare - November/December 2008 - (Page 20) For Anemic Cancer Patients With Metastatic, Non-myeloid Malignancies Receiving Chemotherapy… CONTROL THE RESPONSE MANAGE HEMOGLOBIN AND REDUCE TRANSFUSIONS When Treating Your Patients: • Evaluate for other treatable etiologies of anemia (iron, folate, or B12 deficiency, hemolysis, or bleeding) to treat appropriately • PROCRIT therapy should not be initiated at hemoglobin (Hb) levels 10 g/dL • The dose of PROCRIT should be titrated for each patient to achieve and maintain the lowest Hb level sufficient to avoid the need for red blood cell (RBC) transfusion • The rate of Hb increase should not exceed 1 g/dL in any 2-week period • Monitor Hb weekly until stable, and then regularly during therapy
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.